Armata Pharmaceuticals Inc ARMP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
-
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
-
Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment
-
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
-
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
-
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
-
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
-
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
Trading Information
- Previous Close Price
- $3.66
- Day Range
- $3.66–3.93
- 52-Week Range
- $3.09–16.34
- Bid/Ask
- $3.60 / $4.00
- Shares Outstanding
- 37.18M
- Market Cap
- $143.15M
- Volume/Avg
- 114,680 / 209,485
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 61
- Website
- https://www.armatapharma.com
Valuation
|
Metric
|
ARMP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ARMP
|
|---|---|
Quick Ratio | 0.11 |
Current Ratio | 0.11 |
Interest Coverage | −8.01 |
Quick Ratio
ARMP
Profitability
|
Metric
|
ARMP
|
|---|---|
Return on Assets (Normalized) | −222.45% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −215.76% |
Return on Assets
ARMP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Bjcz&> | LOCK|@jh! | $127B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#w#y><d | LOCK|XRh> | $76B | |||
| Moderna Inc
MRNA
| LOCK|N&^b@k | LOCK|?% | $75B | |||
| argenx SE ADR
ARGX
| LOCK|rBV%vL | LOCK|?^ | $59B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H$HlHy@ | LOCK|W#J | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Y@gymv | LOCK|gn!Kt | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%Fvhvd#< | LOCK|<b>@ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|#$??G! | LOCK|?#! | $24B | |||
| Incyte Corp
INCY
| LOCK|wJX%&?k | LOCK|&? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|rBmlKQ< | LOCK|SpQ | $15B |
United States